Litigation in Generic Pharmaceutical Markets: How Patent Disputes Delay Affordable Medicines

When a brand-name drug’s patent expires, you’d expect cheaper generic versions to hit the market quickly. But in reality, it often takes years longer - not because of science or manufacturing delays, but because of legal battles fought in courtrooms and patent offices. This isn’t about innovation. It’s about extending monopoly profits. The system meant to speed up access to affordable medicines has become a tool to block them.

How the System Was Supposed to Work

The Hatch-Waxman Act of 1984 was designed to strike a balance. It gave brand-name drug companies extra patent time to make up for the years spent in FDA approval. In return, it created a fast-track path for generic manufacturers to enter the market. All they had to do was file an Abbreviated New Drug Application (ANDA) and certify that the brand’s patents were either invalid or wouldn’t be infringed. That’s called a Paragraph IV certification.

When a generic company files a Paragraph IV challenge, the brand company has 45 days to sue. If they do, the FDA can’t approve the generic for 30 months - a built-in pause called the 30-month stay. The idea was to give both sides time to resolve disputes without blocking patient access indefinitely. But over time, the pause became a weapon.

The Orange Book: A Legal Trapdoor

The Orange Book is the FDA’s official list of patents tied to brand-name drugs. It’s supposed to include only patents that cover the active ingredient, how the drug is used, or how it’s made. But in practice, companies have turned it into a fishing net. They list patents for everything: the shape of the pill, the color of the capsule, the design of the inhaler, even the packaging.

In 2025, a landmark ruling in Teva v. Amneal over the asthma inhaler ProAir® HFA changed that. Judge Chesler ruled that patents on the inhaler’s dose counter didn’t qualify because they didn’t claim the actual drug - albuterol sulfate. That’s a big deal. It means roughly 15-20% of patents currently listed in the Orange Book might be illegal under existing law. Yet, hundreds of these questionable patents remain on the books.

The Association for Accessible Medicines (AAM) found that brand companies routinely use this loophole to file multiple lawsuits over different patents, one after another. When one patent expires or gets invalidated, they sue again using a new one. This tactic, called serial patent litigation, can delay generic entry for 7 to 10 years after the original patent expires.

Where the Lawsuits Happen - and Why

Not all courts are created equal. The Eastern District of Texas has become the go-to venue for pharmaceutical patent cases. In 2024, it handled 38% of all patent lawsuits - more than double the next busiest district. Why? Because its judges are experienced in patent law, procedures favor plaintiffs, and juries tend to side with patent holders. Generic companies know this. They avoid filing there. Brand companies? They file there - and they win more often.

The Western District of Texas and the District of Delaware follow, but neither comes close. This isn’t about justice. It’s about forum shopping - choosing the court most likely to rule in your favor. And it’s costing patients. Every extra month of delay means higher drug prices and fewer treatment options.

Settlements That Delay More Than They Help

You might think settlements end these fights. But many don’t. In fact, some settlements are designed to keep generics off the market longer.

The FTC has spent years fighting so-called pay-for-delay deals - where brand companies pay generic makers to stay out of the market. For example, a brand might pay a generic company millions to delay launching its version until after the patent expires. The FTC says this is anticompetitive. Courts have agreed in some cases, but enforcement remains inconsistent.

Yet here’s the twist: a 2025 report from the IQVIA Institute, funded by AAM, found that patent settlements actually brought generics to market five years earlier on average than if litigation went to trial. How? Because without the option to settle, many generic companies just won’t file Paragraph IV challenges at all. They can’t afford the risk. So settlements, even imperfect ones, can speed things up.

But that doesn’t excuse the bad actors. When a brand company lists 67 patents on a single drug like Eliquis, or 152 on semaglutide (Ozempic, Wegovy), it’s not protecting innovation - it’s building a legal wall.

The Human Cost

Behind every delayed generic is a patient who can’t afford their medicine.

The FTC estimates that improper patent listings block generic competition for about 1,000 drugs every year. That costs the U.S. healthcare system $13.9 billion annually. For cancer patients on drugs like Eliquis or Humira, that’s not just money - it’s life or death. One study showed oncology drugs take an average of 5.7 years after patent expiration to see generic versions - even though the active ingredient is no longer protected.

Meanwhile, the average time from brand approval to first generic entry has doubled since 2005 - from 14 months to 28 months. That’s not progress. That’s obstruction.

What’s Changing - and What’s Not

There are signs of change. The FTC and DOJ held joint listening sessions in March 2025 where 12 generic manufacturers testified about how brand companies listed patents on manufacturing equipment and packaging to delay competition. The FDA is now proposing new rules that would require brand companies to certify under penalty of perjury that every patent listed in the Orange Book meets legal standards. Those rules could take effect in mid-2026.

Generic companies are also turning to the Patent Trial and Appeal Board (PTAB) for inter partes review (IPR) - a faster, cheaper way to challenge patents outside of court. IPR filings against pharma patents jumped 47% between 2023 and 2024. But the Supreme Court’s 2025 decision in Smith & Nephew v. Arthrex made it harder for generic companies to file these challenges, requiring them to prove direct harm - something many can’t do.

The number of patents per drug keeps climbing. For small molecule drugs, it’s now 37 on average. For biologics and biosimilars? 78. Oncology drugs? Over 200. That’s not innovation. That’s a patent thicket - a maze of overlapping claims designed to confuse, delay, and deter.

What Needs to Happen Next

The system is broken. It’s not failing because of bad actors alone - it’s failing because the rules haven’t kept up.

First, the FDA needs to enforce its own rules. If a patent doesn’t claim the drug itself, it shouldn’t be in the Orange Book. Period. Second, Congress needs to limit serial litigation. No more patent stacking. No more 10-year delays. Third, pay-for-delay settlements need stricter penalties - not just fines, but automatic bans on future patent listings.

Generic manufacturers need more protection. Right now, they’re stuck between a rock and a hard place: sue and risk bankruptcy, or don’t sue and let prices stay high. The law should protect them for challenging bad patents - not punish them for it.

Patients shouldn’t have to wait years for a drug that’s already been proven safe and effective. The science is ready. The generics are ready. The only thing holding them back is the law - and the companies exploiting it.